Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine. - O'Connell CL; Baer MR; Ørskov AD; Saini SK; Duong VH; Kropf P; Hansen JW; Tsao-Wei D; Jang HS; Emadi A; Holmberg-Thyden S; Cowland J; et al. (Clinical cancer research : an official journal of the American Association for Cancer Research, 2022)